Pune, India | January 02, 2026
Aurobindo Pharma has successfully acquired Khandelwal Laboratories’ non-oncology prescription business through a ₹325 crore deal. This acquisition enhances the company’s domestic formulations segment and strengthens its presence in key therapeutic areas.
The deal transfers 23 established brands and nine pipeline products spanning 67 SKUs. That primarily focused on anti-infective and pain management therapies. By integrating these products, Aurobindo can expand its branded prescription offerings and gain immediate market share.
Although the transaction does not include equity ownership of Khandelwal Laboratories. It brings a field force of approximately 470 personnel and a distribution network exceeding 1,600 stockists. Consequently, Aurobindo can leverage existing operational infrastructure to maximize reach and sales efficiency.
Khandelwal’s non-oncology operations reported ₹113.5 crore turnover in fiscal 2024‑25. It demonstrates a stable and profitable business that reinforces the rationale behind the deal. Analysts believe this acquisition will provide Aurobindo with immediate scale in a competitive domestic market.
Importantly, the ₹325 crore deal did not require regulatory approvals and does not involve a related-party transaction. It ensures smooth integration and seamless operational continuity for both companies.
Industry experts suggest the deal strengthens Aurobindo Pharma’s competitive positioning, particularly in the pain management and anti-infective prescription segments. The company can leverage Khandelwal’s brand recognition to increase prescription reach and market penetration.
Structured as a slump sale, the ₹325 crore deal includes customary working capital adjustments. This ensures financial transparency, protects both parties, and enables Aurobindo to integrate operations without disruption.
Khandelwal Laboratories, established in the 1970s, has maintained strong brand equity and consistent revenue streams across India. Its established market presence validates the ₹325 crore deal and provides long-term strategic benefits.
Following the announcement, Aurobindo Pharma shares responded positively, reflecting investor confidence in the company’s growth strategy through targeted acquisitions like the ₹325 crore deal.
Integration of Khandelwal’s business is expected to optimize operational efficiency, enhance sales force effectiveness, and improve product distribution, particularly in semi-urban and rural healthcare areas.
Senior executives stated that the ₹325 crore deal complements Aurobindo’s strategic vision, expanding its branded prescription portfolio while meeting evolving healthcare needs nationwide. The acquisition aligns with the company’s long-term commitment to sustainable growth.
Industry observers predict that the deal may inspire additional consolidation in India’s non-oncology pharmaceutical segment, prompting competitors to pursue strategic acquisitions for market expansion.
In conclusion, the ₹325 crore deal significantly strengthens Aurobindo Pharma’s domestic formulations portfolio, improves operational reach, and positions the company for sustained growth across India’s competitive pharmaceutical sector.
